|
|
|
Trastuzumab is indicated as a first line treatment, in combination with paclitaxel, for metastatic HER2 overexpressing breast cancer, and as monotherapy in patients who have previously received one or more chemotherapy regimens in the metastatic setting <a href=https://fastpriligy.top/>priligy online pharmacy</a> |
|
发表于